InterVenn is developing a new benchmark-performance diagnostic test for ovarian cancer. VOCAL is a multi-site, international prospective clinical validation trial that seeks to establish whether a simple blood test can enable clinicians to distinguish with high predictive accuracy benign from malignant tumors in women presenting with a pelvic mass.

Ovarian cancer causes more deaths than any other cancer of the female reproductive system, in part because currently available tests are unreliable. Early and accurate diagnosis of ovarian cancer will improve survival, as treatment works best when cancer is detected in its early stages, and at the same time help avoid unnecessary and potentially harmful surgical intervention in patients who don’t need it.